Phase III Randomized Study of Induction Therapy Comparing Daunorubicin With Idarubicin Followed By Consolidation Therapy Comparing High-Dose Cytarabine With Sequential Multiagent Chemotherapy in Patients With Previously Untreated De Novo Acute Myeloid Leukemia (JALSG AML201 Study)
Phase 3
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- JPRN-C000000157
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 850
Inclusion Criteria
Not provided
Exclusion Criteria
1.Atypical leukemia 2.History of MDS 3.History of cancer chemotherapy 4.Other active neoplasms 5.Recent history of myocardial infarction or renal failure, 6.Severe comorbidity (diabetes mellitus, infection or liver cirrhosis) 7.Psychological disorders 8.Pregnant and/or lactating woman 9.Positive anti-HIV antibody
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method